Vericel Corp. (VCEL)

[commoncentsinvestor]

Amazing praise coming from the CEO of Histogenics at there earnings call. When asked about the competition here's what he said:

Adam Gridley

Sure. Great question, Brandon. And I think you're spot on. The competition has created substantial awareness over the last year. They've had a fantastic launch in our opinion and kudos to them from the team here at Histogenics. We've been really pleased to see the market awareness that is increasing. I think there's a general excitement that they're starting to beat some new cartilage therapies that are hopefully going to provide better outcomes than some of the surgical procedures or some of the first generation products.

Until very first Macy program launched about a year in quarter ago, they reported some great results last week. They've seen robust reimbursement coverage, and I think that both surgeons, patients, and investors as well are really starting to pay attention to this space. I think that this for us and other competitors is positive overall. This is an extremely large market. The Macy team is focused on a number of the sort of larger lesion activities. Some of the previous cartilage cell surgeons and they've just done a tremendous job educating, training, and creating awareness for that product.